Risk-Taking: Clinical Trials

18 trials for Risk-Taking, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed. 18 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 218Completed 18
Phase 14Completed 4
Phase 31Completed 1

Follow Risk-Taking: new trials by email Literature Review of Risk-Taking trials Research Report on Risk-Taking

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray
Naloxone hydrochloride 20mg/ml - Gambling, Opioid
Phase 2CompletedFinnish Institute for Health and Welfare202017-02-142019-09-12
BEing Safe in Treatment
BEST assessment only, BEST assessment plus feedback report, Standard Counselor Training - Risk Behavior, Sex, Unsafe
Phase 2CompletedUniversity of Washington5372015-06-012018-07-02
Milk Thistle in Pathological Gambling
Placebo, Milk Thistle - Pathological Gambling, Gambling Disorder
Phase 2CompletedUniversity of Chicago552015-01-012026-07-07
XY-Zone Program Evaluation: A School-Based Dropout Prevention Program for At-Risk Youth
XY-Zone - Adolescent Problem Behavior at School, Risk Behavior
Phase 1 / Phase 2CompletedUniversity of Texas at Austin912011-08-012013-07-10
Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial
Family Therapy based on Structural Family Therapy, Group Therapy, Psychoeducational Sessions - Substance Use Disorders, Risk Behavior
Phase 2CompletedUniversity of Miami1902011-01-012015-12-16
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
Ecopipam - Pathological Gambling
Phase 2CompletedEmalex Biosciences Inc.342010-10-012024-05-14
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
N Acetyl Cysteine, Sugar Pill - Gambling, Tobacco Use Disorder
Phase 2CompletedUniversity of Chicago282009-09-012023-03-21
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement
Haloperidol, Fluphenazine, Dexedrine - Pathological Gambling
Phase 2CompletedCentre for Addiction and Mental Health602009-09-012016-04-25
Tolcapone Treatment of Pathological Gambling
Tolcapone - Pathological Gambling
Phase 2CompletedUniversity of Chicago242009-06-012023-02-23
Topiramate Trial for Pathological Gamblers
Topiramate flexible dosage, Placebo matching tablets, 4-session gambling cognitive restructuring - Pathological Gambling
Phase 2CompletedUniversity of Sao Paulo382009-06-012013-05-03
Investigation of Naltrexone for Pathological Gambling
Naltrexone, Placebo - Pathological Gambling
Phase 2CompletedYale University92009-02-012017-10-13
Memantine Treatment Study of Pathological Gambling
Memantine Hydrochloride - Pathological Gambling
Phase 2CompletedYale University292007-12-012013-04-08
Cognitive Behavioral Therapy for Pathological Gambling
Cognitive Behavioral Therapy, Wait-list - Pathological Gambling
Phase 2CompletedUniversity of Minnesota762006-06-012010-01-05
Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women
Healthy Love Workshop, HIV/AIDS 101 Workshop - HIV Infections, Sexually Transmitted Infections
Phase 1 / Phase 2CompletedCenters for Disease Control and Prevention3132006-05-012010-05-14
Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM
Many Men, Many Voices (3MV) - HIV Infections, Sexually Transmitted Diseases
Phase 1 / Phase 2CompletedCenters for Disease Control and Prevention3412005-08-012010-06-24
Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling
nalmefene HCl, Placebo - Pathological Gambling
Phase 2 / Phase 3CompletedSomaxon Pharmaceuticals2332005-08-012008-05-19
Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents
Preventing AIDS Through Live Movement and Sound (PALMS) - Hiv
Phase 1 / Phase 2CompletedCenters for Disease Control and Prevention2642005-03-012026-05-11
Indicated Prevention With At-Risk Gamblers
Personalized Feedback Intervention, Cognitive Behavioral Intervention - Gambling, Pathological Gambling
Phase 2CompletedUniversity of Washington2252003-07-012013-12-11

Narrower conditions

Gambling (12)  ·  Safe Sex (3)  ·  Sexual Behavior (3)  ·  HIV Infections (2)  ·  Sexually Transmitted Diseases (2)  ·  Substance-Related Disorders (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Behavior, Addictive (1)  ·  Homosexuality, Male (1)  ·  Mental Disorders (1)  ·  Risk Reduction Behavior (1)  ·  Tobacco Use Disorder (1)  ·  Unsafe Sex (1)

Broader conditions

Behavior (18)  ·  Mental Disorders (13)  ·  Disruptive, Impulse Control, and Conduct Disorders (12)  ·  Blood-Borne Infections (3)  ·  Chemically-Induced Disorders (3)  ·  Communicable Diseases (3)  ·  Genital Diseases (3)  ·  Immune System Diseases (3)  ·  Immunologic Deficiency Syndromes (3)  ·  Infections (3)  ·  Lentivirus Infections (3)  ·  RNA Virus Infections (3)  ·  Retroviridae Infections (3)  ·  Sexually Transmitted Diseases, Viral (3)

Interventions

Sugars (2)  ·  Acetylcysteine (1)  ·  Cognitive Behavioral Therapy (1)  ·  Dextroamphetamine (1)  ·  Fluphenazine (1)  ·  Haloperidol (1)  ·  Lactose (1)  ·  Memantine (1)  ·  Naloxone (1)  ·  Naltrexone (1)  ·  Psychotherapy, Group (1)  ·  Silymarin (1)  ·  Sound (1)  ·  Tolcapone (1)  ·  Waiting Lists (1)

Sponsors

Centers for Disease Control and Prevention (3)  ·  University of Chicago (3)  ·  University of Washington (2)  ·  Yale University (2)  ·  Centre for Addiction and Mental Health (1)  ·  Emalex Biosciences Inc. (1)  ·  Finnish Institute for Health and Welfare (1)  ·  Somaxon Pharmaceuticals (1)  ·  University of Miami (1)  ·  University of Minnesota (1)  ·  University of Sao Paulo (1)  ·  University of Texas at Austin (1)

Countries

United States (13)  ·  Brazil (1)  ·  Canada (1)  ·  Finland (1)

Top investigators

Jeffrey H Herbst, PhD (3)  ·  Thomas M Painter, PhD (3)  ·  Jon E Grant, MD, JD (2)  ·  Jon E Grant, MD, JD, MPH (2)  ·  Daniel A. Santisteban, Ph.D. (1)  ·  Daniela Lobo, MD, Ph.D. (1)  ·  David W Springer, PhD (1)  ·  Dazon Dixon Diallo, MPH (1)  ·  Donald Black, MD (1)  ·  Hannu Alho, Prof. (1)  ·  Jennifer Lauby, PhD (1)  ·  Jon E Grant, JD, MD, MPH (1)  ·  Jon Grant, MD (1)  ·  Katherine L Montgomery, PhD, MSSW (1)  ·  Maite P. Mena, Psy.D. (1)

Results publications

PMID 36130734, PMID 19267264, PMID 20135214, PMID 20721537, PMID 22188239, PMID 23586456, PMID 23953269, PMID 24345329, PMID 24743662, PMID 24743663, PMID 25166480, PMID 35751944, PMID 36919514, PMID 38478366

NIH funding

1RC1DA028279-01 (1), K23MH069754 (1), R01DA027920 (1), R01HD078163 (1), R21MH067026 (1)